1. Nakanoshima Qross TOP
  2. News
  3. On Thursday, March 5th, we held the "NQ Global Startup Gateway (Nakanoshima Cross Global Startup Creation and Hub Promotion Project) NQ version Bio-Catalyst AI Accelerator Program Report Meeting."

NewsNews

On Thursday, March 5th, we held the "NQ Global Startup Gateway (Nakanoshima Cross Global Startup Creation and Hub Promotion Project) NQ version Bio-Catalyst AI Accelerator Program Report Meeting."

Activity report
2026.03.31

On Thursday, March 5th, we held the "NQ Global Startup Gateway (Nakanoshima Cross Global Startup Creation and Hub Promotion Project) NQ version Bio-Catalyst AI Accelerator Program Report Meeting" at the Qrossover Lounge Yume on the 2nd floor of Nakanoshima Qross.

This event was held to report on the results of the "NQ Bio-Catalyst AI Accelerator Program," which was implemented as part of the "NQ Global Startup Gateway" organized by Osaka Prefecture.

In this program

  • Shinya Yamamoto, General Manager, Deep Intelligent Pharma Co., Ltd. (Lecturer)
  • Yu Moriguchi, Assistant to the Chairman, Japan Medical Promotion Foundation (Lecturer)
  • Mari Kobayashi, MIRACLE SCIENCE INNOVATION Co., Ltd. (Supporter)

We welcomed the above three individuals as instructors and program supporters, and, leveraging their expertise in AI, deep tech, and global knowledge, provided the following support for startup launches through face-to-face and communication tool-based mentoring.

  • Support for obtaining public subsidies such as AMED
  • Support for creating Target Product Profiles (TPPs)
  • Support for developing a business model for clinical trial protocol creation for PMDA (Pharmaceuticals and Medical Devices Agency)
  • Support for intellectual property strategy formulation and prioritization, etc.

On the day of the event, the selected participants presented the results they had achieved through the program, and the instructors provided comments. Through each presentation and comment, many insights were gained for future startup establishment and commercialization, including the acceleration of business planning and research and development using AI.

At the opening of the event, Mr. Akihiro Nishino, Director of the Life Sciences Industry Division, Growth Industry Promotion Office, Department of Commerce, Industry and Labor, Osaka Prefecture, gave an opening address. He outlined Osaka Prefecture's efforts to build a startup ecosystem centered around Nakanoshima Cross, and emphasized the importance of supporting startups by utilizing AI, deep tech, and global expertise. He also expressed his hope that this briefing would serve as a reference for future business development for researchers and startups, and as an opportunity for collaboration and investment for operating companies and VCs.

In the subsequent program explanation, it was shared that, amidst the rapid evolution of AI, its use is becoming standard practice for researchers and startups. The program's concrete results were presented, demonstrating how even short-term mentoring can accelerate business strategy development, intellectual property management, and research plan formulation. The necessity of shifting to AI-based research and development and business models, as well as the importance of the ability to articulate tacit knowledge and design processes, were emphasized, and it was explained that this program is positioned as a practical platform for these skills.

Next, in the results presentation by the selected participants, the 11 participants who were selected for this program presented their achievements during the program period in a pitch format. Following each presentation, the instructors provided comments, summarizing the content and offering insights for future business development and research and development.

The presentation demonstrated the potential of using AI to develop research, clinical practice, and business simultaneously and in a multifaceted manner. Examples were presented of businesses that initially started as a single concept but have expanded into multiple areas, such as building clinical data infrastructure, supporting research, and improving emergency medical care.

It has been reported that by utilizing AI in research planning, clinical protocols, statistical analysis plans, and application document creation, the initial processes toward practical application and funding acquisition can be advanced with high quality and speed. This suggests that collaboration between researchers with expertise and tacit knowledge and AI has the potential to maximize research results and lead to the commercialization and social implementation of research seeds.

The overall assessment highlighted the potential of practical models for commercializing research seeds and forming ecosystems centered on AI utilization. Through this program, it was confirmed that even in small-scale and limited-funding environments, researcher-led commercialization becomes a realistic option by utilizing AI, enabling researchers to pursue social implementation while balancing research and entrepreneurship.

Furthermore, in the age of AI, in addition to research capabilities, the "production ability" to communicate the value of research to society and the market is crucial, and it was demonstrated that with appropriate support, excellent research seeds can develop into businesses that can be deployed globally. Moreover, it was confirmed that the program demonstrated the ability to produce results in a short period of time, and that the cross-disciplinary collaboration based at Nakanoshima Cross will serve as a foundation to accelerate the social implementation of future research seeds.

In the closing remarks, Mr. Miyagawa of MSI summarized that this program demonstrated that the early commercialization of AI-driven research seeds is not merely a "possibility" but a "feasible option," and that the actions and results of the researchers who took on this challenge provided a tangible sense of creating new value from Osaka.

Osaka Prefecture and Nakanoshima Cross will continue similar initiatives to this program, working to support the creation and growth of businesses by researchers and startups. We hope you will continue to follow these activities.

[List of selected companies and academia]

Kazuhiro Ikumi, Representative Director, MEDICOLAB Co., Ltd.
Programmed medical device for early detection of Parkinson's disease and dementia

Ryotaro Tani, Representative Director, Eudaimonix Co., Ltd.
Developing devices to solve the problems faced by patients with colostomy and fecal incontinence

Ken Okamoto, Co-founder and CSO of PurinoScience Inc. (before its establishment)
Oral treatment for sarcopenia
Functional recovery approach through reactivation of the ATP salvage pathway

Kazuma Yamakawa, Associate Professor, Department of Emergency Medicine, Osaka Medical and Pharmaceutical University
Diverse business development aimed at improving on-site medical care and supporting research through the use of AI.

Megumi Madono, Associate Professor, Lifestyle Medicine Endowed Chair, Department of Endocrinology and Metabolism, Graduate School of Medicine, Osaka University
Building a social implementation platform for Food is Medicine, with Teaching Kitchen at its core.

Hiroaki Abe, Specially Appointed Researcher, Department of Immunocellular Biology, Graduate School of Medicine, Osaka University
Development of wide-area biopsy and ultra-rapid intraoperative diagnosis using multiphoton excitation microscope

Kenji Nakamura, Research Director, Professor, and Visiting Professor, Osaka University of Health Sciences / Osaka University
Exploratory clinical study of allogeneic synovial mesenchymal stem cell-derived three-dimensional artificial tissue (gMSC1) transplantation for knee joint meniscus injury

Mikio Hayashi, Lecturer, Department of Physiology, Faculty of Medicine, Kansai Medical University
Development of novel oral anticancer drugs targeting cancer stem cells

Naoto Kinashi, Special Research Fellow, iCeMS, Kyoto University
Development of the world's first implantation promoter based on integrin activation

Kenji Takagi, Chief of Coronary Artery Disease Department, Cardiovascular Medicine Division, National Cerebral and Cardiovascular Center
Next-generation navigation AI that guides cardiac catheterization procedures accurately and without burden using only contrast-enhanced images.

Shinichi Nakagawa, Part-time Lecturer/Department Head, Department of Rehabilitation, Hyogo College of Medicine/Midorioka Hospital
Development of an order processing system for medical devices utilizing AI technology.

■NQ version Bio-Catalyst AI Accelerator Program
This program leverages Deep Intelligent Pharma's cutting-edge AI technology and global industry expertise to transform promising startups into investable companies.
Details:https://nq-gateway.jp/programs#bio

To List